Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT04215471 Recruiting - Clinical trials for Oesophageal Squamous Cell Carcinoma

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma

NATION1907II
Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

The investigators will conduct a prospective, single-arm study to evaluate the safety and feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in patients with resectable esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT04212598 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Start date: August 3, 2020
Phase: Phase 2
Study type: Interventional

Esophageal cancer is a kind of disease with high incidence and mortality. Definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma. To Investigate the value of immunotherapy consolidation in locally advanced esophageal squamous cell carcinoma after completing radical concurrent chemoradiotherapy.

NCT ID: NCT04204837 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Skin

Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Start date: March 6, 2017
Phase: Phase 2
Study type: Interventional

To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)

NCT ID: NCT04196985 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC

HENEPET
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients. Forty patients aged more than 18 years who have a histologically confirmed HNSCC and have received chemoradiation therapy will be recruited for the study. The patients will be scanned with both PET/CT and PET/MRI 12 weeks after the end of CRT.

NCT ID: NCT04191460 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer

GuidedbyLight
Start date: July 12, 2022
Phase: Phase 2
Study type: Interventional

This is a two-staged clinical trial to investigate the feasibility of intraoperative Fluorescence Imaging (FLI) to adequately assess tumor margins in patients with oral cancer using cRGD-ZW800-1.

NCT ID: NCT04188665 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Using MASL to Combat Oral Cancer

Start date: January 29, 2021
Phase: Early Phase 1
Study type: Interventional

This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

NCT ID: NCT04183166 Recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Start date: December 12, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

NCT ID: NCT04180215 Recruiting - Clinical trials for HPV-Related Squamous Cell Carcinoma

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Start date: December 11, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.

NCT ID: NCT04174079 Recruiting - Clinical trials for Thoracic Esophageal Squamous Cell Carcinoma

Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma

Start date: December 11, 2019
Phase: N/A
Study type: Interventional

Patients with thoracic esophageal squamous cell carcinoma after total two-field lymph node dissection were randomized into the adjuvant chemotherapy group or the postoperative observation group

NCT ID: NCT04170257 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions

Start date: October 18, 2019
Phase: N/A
Study type: Interventional

The investigators aim to evaluate the performance of Narrow Band Imaging (NBI) endoscopy in Esophageal Squamous Cell Carcinoma (ESCC) screening, as compared to the currently used White Light Endoscopy (WLE) and Lugol's Iodine Staining Endoscopy (ISE). NBI is a simple, safe and non-invasive technique, which can provide real-time optical staining for suspicious lesions. This trial is designated to enroll 10000 participants from five centers located in different regions (North, West and South) in China, which would provide real-world evidence for the recommendation of endoscopic diagnostic technique used in ESCC screening projects.